Results 41 to 50 of about 53,817 (192)
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
, 2015 Erlotinib is currently marketed at fixed standard dosage against pancreatic cancer and non-small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by significant variability that may affect efficacy and tolerability.
Thierry Buclin +17 more
core +1 more source
Erlotinib-responsive actinic keratoses. [PDF]
, 2007 peer reviewedErlotinib is an inhibitor of the tyrosine-kinase domain of the epidermal growth factor receptor-1 (EGFR). This drug is used to treat some solid cancers, particularly advanced non-small-cell lung carcinoma.
Pierard, Gérald +2 more
core +1 more source
Journal of Cancer, 2011 A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer.
Chandra Bartholomeusz, Fumiyuki Yamasaki, Hitomi Saso, Kaoru Kurisu, Gabriel N. Hortobagyi, Naoto T. Ueno
doaj
Erlotinib, Erlotinib–Sulindac versus Placebo:A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer [PDF]
, 2014 PURPOSE: The EGF receptor (EGFR) and COX2 pathways are upregulated in head and neck squamous cell carcinoma (HNSCC). Preclinical models indicate synergistic antitumor activity from dual blockade.
Denq, William +50 more
core +1 more source
Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels
Case Reports in Oncology, 2013 Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer.
M. Czejka +4 more
doaj +1 more source
The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line
Pharmacology Research & Perspectives, 2020 Single nucleotide polymorphisms (SNPs) in the gene for multidrug resistance protein ABCG2, an erlotinib transporter, is a possible contributor to the interindividual variation observed in erlotinib pharmacokinetics and toxicity. Therefore, the aim was to
Anna Svedberg +3 more
doaj +1 more source
A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics
Andrology, EarlyView.ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis +3 more
wiley +1 more source
The two representative erlotinib-senstivive clinical cases treated with erlotinib.
, 2016 (a) Case #1 had exhibited 55.6% of cancer cell growth with erlotinib exposure in CD-DST. The cancer spread to the medianstinal lymph node (Yellow arrows).
Kazumasa Orihashi (2608120) +5 more
core +1 more source
BMC Cancer, 2018 Background Pneumatosis intestinalis (PI) is a rare complication of chemotherapy, characterized by multiple gas accumulations within the bowel wall. Case presentation A 71-year-old woman with epidermal growth factor receptor (EGFR) mutation-positive lung ...
Hironori Uruga +10 more
doaj +1 more source